Further understanding of the impacts of LKB1 deficiency on cancer cell immunogenicity and tumor immune infiltration will facilitate development of new strategies to increase the clinical efficacy of immunotherapy in patients with LKB1 mutated cancers. Here, STK11 is linked to cancer.